Discovery, characterisation and optimisation of bicyclic peptide inhibitors that disarm Staphylococcus aureus a-hemolysin

This study reports the discovery and optimization of bicyclic peptides that effectively neutralize *Staphylococcus aureus* α-hemolysin by blocking its binding to host cells, offering a promising, synthetically accessible anti-virulence therapeutic strategy.

The Gist

The Big Picture: Disarming a Tiny Monster

Imagine Staphylococcus aureus (a common bacteria) as a tiny, mischievous burglar. Usually, we try to kill burglars with "antibiotics" (like a SWAT team). But these burglars are smart; they keep learning how to dodge the SWAT team, becoming "superbugs" that our current weapons can't stop.

This paper proposes a different strategy: Don't kill the burglar; just take away their weapon.

The burglar's weapon is a toxin called Alpha-Hemolysin (Ahly). Think of Ahly as a tiny drill bit that the bacteria uses to punch holes in your cells, causing them to burst and die. The researchers wanted to build a tiny "plug" to stop the drill bit from working.

The Solution: The "Bicycle" Peptides

Instead of using a giant antibody (which is like a heavy, expensive, hard-to-make shield), the researchers used Bicyclic Peptides.

• What are they? Imagine a piece of string (a peptide) that is usually floppy and wiggly. If you tie the ends of the string to a small, rigid metal frame (a "scaffold"), it becomes a stiff, structured shape. Because it has two loops, they call it a "Bicycle."
• Why use them? They are small enough to squeeze into tight spaces (like inside your lungs), cheap to make, and very stable. They act like a custom-made key that fits perfectly into the lock of the toxin.

The Hunt: Finding the Right Key

The researchers didn't guess the shape of the key. They used a method called Phage Display, which is like a high-tech "speed dating" event for molecules.

1. The Library: They created a library of 10 trillion different Bicycle peptides, each with a slightly different shape.
2. The Date: They threw these trillions of peptides at the Alpha-Hemolysin toxin.
3. The Match: Most peptides bounced off. But a few stuck. The researchers kept the ones that stuck, made more copies of them, and tried again.
4. The Winner: After four rounds of this "dating" process, they found a group of winners. Almost all of them had a specific pattern of three letters: W-N-P (Tryptophan-Asparagine-Proline). This was the "secret handshake" the toxin recognized.

The Upgrade: From Good to Great

The first winner (Peptide 14) was good, but not perfect. It was like finding a key that opened the door, but it was a bit loose.

• Tuning the Engine: The researchers took the winning key and made tiny tweaks to its shape (changing a few amino acids). This is called "affinity maturation."
• The Result: They created Peptide 20, which fit much tighter.
• The Super-Charge: Finally, they swapped some of the standard building blocks for "non-canonical" (special, man-made) ones. This created Peptide 88.

Peptide 88 is the champion. It binds to the toxin 20 times tighter than the original winner and is incredibly effective at stopping the toxin from working.

How It Works: The "Plug" Mechanism

The researchers used X-ray crystallography (essentially taking a 3D photo of the molecules) to see exactly how the Bicycle peptide stops the toxin.

• The Dock: The toxin has a specific "rim" or edge that it uses to grab onto your human cells.
• The Block: The Bicycle peptide sits right on that rim, like a cork in a bottle.
• The Lock: The "W-N-P" part of the peptide acts like a specific key that locks into a groove on the toxin. Once locked, the toxin cannot grab onto the cell. It's like putting a piece of gum in a keyhole; the key (the toxin) can't turn, so the door (the cell) stays safe.

The Proof: Saving the Cells

The team tested this in the lab:

1. Red Blood Cells: They mixed the toxin with red blood cells. Without the peptide, the cells popped (lysed). With Peptide 88, the cells stayed intact.
2. Lung Cells: They used human lung cells (A549). The toxin usually kills these cells. Peptide 88 saved them.
3. Real Bacteria: They mixed the peptide with actual S. aureus bacteria. The bacteria tried to attack the lung cells, but Peptide 88 neutralized the toxin, and the cells survived.

Why This Matters

• New Strategy: This is an "anti-virulence" therapy. It doesn't kill the bacteria, so the bacteria don't feel the pressure to evolve resistance as quickly. It just disarms them, letting your immune system clean up the mess.
• Better than Antibodies: Antibodies (like the ones currently in clinical trials) are huge, expensive, and hard to get into tissues. These Bicycle peptides are small, cheap, and can penetrate tissues easily.
• Future Hope: While there is still work to do (like making sure the peptide doesn't get chewed up by enzymes in the body), this study proves that we can design tiny, synthetic "bicycles" to disarm dangerous bacteria.

In a nutshell: The researchers built a tiny, custom-made "cork" that fits perfectly into the "drill bit" of a dangerous bacteria, stopping it from punching holes in your cells, all without killing the bacteria or causing resistance.

Technical Summary

1. Problem Statement

• Antimicrobial Resistance (AMR): Staphylococcus aureus, particularly Methicillin-Resistant S. aureus (MRSA), is a leading cause of global mortality and AMR-related deaths. Traditional antibiotics face diminishing efficacy due to rapid resistance development.
• Virulence as a Target: An alternative strategy is targeting bacterial virulence factors rather than viability. This approach aims to "disarm" the pathogen, reducing selective pressure for resistance and preserving the host microbiome.
• The Target (Ahly): $\alpha$-Hemolysin (Ahly) is a critical pore-forming toxin (PFT) secreted by S. aureus. It causes tissue injury, immune dysregulation, and cell lysis by forming heptameric $\beta$-barrel pores in host cell membranes. It also upregulates the host metalloprotease ADAM10, facilitating bacterial invasion.
• Current Limitations: While anti-Ahly antibodies (e.g., Tosatoxumab, Suvratoxumab) have reached clinical trials, they suffer from high manufacturing costs, poor tissue penetration, and potential immunogenicity. There is a need for smaller, synthetically accessible, and chemically tractable alternatives.

2. Methodology

The study employed a multi-stage pipeline combining phage display, structural biology, and functional assays:

• Phage Display Library Screening:
  • Used M13 phage libraries displaying bicyclic peptides constrained by a TATB (1,3,5-tris(bromoacetyl) hexahydro-1,3,5-triazine) scaffold.
  • Selected against biotinylated AviTag-Ahly using four rounds of panning.
  • Identified enriched sequences via sequencing and validated binding using AlphaScreen assays.
• Lead Optimization:
  • Affinity Maturation: Iterative rounds of selection on libraries with randomized residues around the initial hit (Peptide 14) to improve binding affinity.
  • Non-Canonical Amino Acids (ncAAs): Systematic substitution of residues with ncAAs (e.g., norleucine, 4-fluorophenylalanine) to enhance hydrophobic interactions and stability.
  • Alanine Scanning: Systematic substitution of residues to alanine to map critical binding epitopes.
• Structural Characterization:
  • Solved a 2.2 Å co-crystal structure of the optimized peptide (Peptide 20) bound to an Ahly monomer mutant (Ahly$^{H35A}$) to prevent spontaneous pore formation.
• Functional Assays:
  • Hemolysis: Measured inhibition of rabbit red blood cell lysis.
  • Cell Binding: Flow cytometry using Alexa Fluor 647-labeled Ahly$^{H35A}$ on A549 human lung epithelial cells.
  • ADAM10 Activation: FRET-based assay to measure Ahly-induced ADAM10 protease activity.
  • Cytotoxicity: LDH release and live/dead staining in A549 cells exposed to recombinant Ahly and live S. aureus co-cultures.
  • Stability: LC-MS analysis of peptide degradation in S. aureus supernatants.

3. Key Contributions

• Discovery of a Novel Motif: Identified a highly conserved WNP (Trp-Asn-Pro) motif in bicyclic peptides that is essential for Ahly binding.
• Structural Insight: Determined the first high-resolution structure of a bicyclic peptide bound to Ahly, revealing the binding footprint on the "rim domain" of the toxin.
• Mechanism Validation: Demonstrated that bicyclic peptides mimic antibody inhibition mechanisms (specifically the antibody LTM14) but with a much smaller molecular footprint.
• Optimization Pipeline: Successfully progressed a lead hit (Peptide 14, $K_D \approx 1.8 \mu M$) to a lead candidate (Peptide 88, $K_D = 96 nM$) through affinity maturation and ncAA incorporation.

4. Key Results

• Discovery & Binding:
  • From 245 sequenced clones, 69% contained the WNP motif.
  • Peptide 14 was the initial hit ($K_D = 1.8 \mu M$).
  • Peptide 20 (affinity matured) achieved $K_D = 609 nM$.
  • Peptide 88 (incorporating ncAAs like norleucine) achieved the highest affinity with $K_D = 96 nM$.
• Structural Mechanism:
  • Peptides bind to a concave pocket on the Ahly rim domain, the site responsible for initial interaction with host cell membranes.
  • The WNP motif is critical: Trp9 sits in a hydrophobic cleft, while Asn10 forms a specific hydrogen bond with Ala207 of Ahly. Pro11 induces a kink to position Asn10 correctly.
  • The binding pose closely resembles the antibody LTM14 (which uses a WRP motif), confirming a privileged epitope on Ahly.
• Functional Inhibition:
  • Hemolysis: Peptide 88 inhibited Ahly-mediated hemolysis with an $IC_{50}$ of 33 $\mu M$ (compared to 504 $\mu M$ for Peptide 14).
  • Cell Binding: Peptide 88 blocked Ahly binding to A549 cells in a dose-dependent manner.
  • ADAM10: Peptide 88 inhibited Ahly-driven upregulation of ADAM10 activity.
  • Cellular Protection: Peptide 88 protected A549 cells from cytotoxicity induced by both recombinant Ahly and live S. aureus (strain 8325-4) co-culture.
• Stability & Specificity:
  • Peptide 88 showed no toxicity to A549 cells.
  • It did not inhibit S. aureus growth (confirming anti-virulence, not bactericidal, activity).
  • Limitation: Peptide 88 showed some susceptibility to proteolytic degradation by S. aureus supernatants, which likely contributes to reduced potency in whole-cell co-culture assays compared to recombinant toxin assays.

5. Significance

• New Therapeutic Modality: This study validates bicyclic peptides as a viable, small-molecule alternative to antibodies for targeting bacterial virulence factors. They offer advantages in tissue penetration, manufacturing cost, and chemical tractability.
• Anti-Virulence Strategy: By disarming S. aureus via Ahly neutralization, these peptides could treat infections without driving resistance as aggressively as traditional antibiotics.
• Clinical Potential: The identified WNP motif and the structural insights provide a blueprint for designing next-generation inhibitors with picomolar affinity and improved proteolytic stability (e.g., via D-amino acids or N-methylation).
• Broad Applicability: The success of the Bicycle phage display platform against a bacterial toxin suggests its utility in developing countermeasures against other AMR pathogens and virulence factors.

In conclusion, the authors successfully engineered a bicyclic peptide (Peptide 88) that effectively neutralizes S. aureus $\alpha$-hemolysin, protects human cells from toxin-induced damage, and represents a promising candidate for future anti-virulence therapeutics.